Complete SPL Sections
1 INDICATIONS AND USAGE
Indications & Usage Section
Pregabalin capsules are indicated for: Management of neuropathic pain associated with diabetic peripheral neuropathy Management of postherpetic neuralgia Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older Management of fibromyalgia Management of neuropathic pain associated with spinal cord injury
2 DOSAGE AND ADMINISTRATION
Dosage & Administration Section
3 DOSAGE FORMS AND STRENGTHS
Dosage Forms & Strengths Section
Capsules: 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg [see Description ( 11 ) and How Supplied/Storage and Handling ( 16 )]
4 CONTRAINDICATIONS
Contraindications Section
Pregabalin capsules are contraindicated in patients with known hypersensitivity to pregabalin or any of its components. Angioedema and hypersensitivity reactions have occurred in patients receiving pregabalin therapy [see Warnings and Precautions ( 5.2 )].
5 WARNINGS AND PRECAUTIONS
Warnings And Precautions Section
6 ADVERSE REACTIONS
Adverse Reactions Section
The following serious adverse reactions are described elsewhere in the labeling: Angioedema [see Warnings and Precautions (5.1)] Hypersensitivity [see Warnings and Precautions (5.2)] Suicidal Behavior and Ideation [see Warnings and Precautions (5.3)] Respiratory Depression [see Warnings and Precautions (5.4)] Dizziness and Somnolence [see Warnings and Precautions (5.5)] Increased Risk of Adverse Reactions with Abrupt or Rapid Discontinuation [see Warnings and Precautions (5.6)] Peripheral Edema [see Warnings and Precautions (5.7)] Weight Gain [see Warnings and Precautions (5.8)] Tumorigenic Potential [see Warnings and Precautions (5.9)] Ophthalmological Effects [see Warnings and Precautions (5.10)] Creatine Kinase Elevations [see Warnings and Precautions (5.11)] Decreased Platelet Count [see Warnings and Precautions (5.12)] PR Interval Prolongation [see Warnings and Precautions (5.13)]
7 DRUG INTERACTIONS
Drug Interactions Section
Since pregabalin is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans (less than 2% of a dose recovered in urine as metabolites), and does not bind to plasma proteins, its pharmacokinetics are unlikely to be affected by other agents through metabolic interactions or protein binding displacement. In vitro and in vivo studies showed that pregabalin is unlikely to be involved in significant pharmacokinetic drug interactions. Specifically, there are no pharmacokinetic interactions between pregabalin and the following antiepileptic drugs: carbamazepine, valproic acid, lamotrigine, phenytoin, phenobarbital, and topiramate. Important pharmacokinetic interactions would also not be expected to occur between pregabalin and commonly used antiepileptic drugs [see Clinical Pharmacology ( 12 )] . Pharmacodynamics Multiple oral doses of pregabalin were coadministered with oxycodone, lorazepam, or ethanol. Although no pharmacokinetic interactions were seen, additive effects on cognitive and gross motor functioning were seen when pregabalin was coadministered with these drugs. No clinically important effects on respiration were seen.
8 USE IN SPECIFIC POPULATIONS
Use In Specific Populations Section
9 DRUG ABUSE AND DEPENDENCE
Drug Abuse And Dependence Section
10 OVERDOSAGE
Overdosage Section
Signs, Symptoms and Laboratory Findings of Acute Overdosage in Humans In the postmarketing experience, the most commonly reported adverse events observed with pregabalin when taken in overdose include reduced consciousness, depression/anxiety, confusional state, agitation, and restlessness. Seizures and heart block have also been reported. Deaths have been reported in the setting of lone pregabalin overdose and in combination with other CNS depressants. Treatment or Management of Overdose There is no specific antidote for overdose with pregabalin. If indicated, elimination of unabsorbed drug may be attempted by emesis or gastric lavage; observe usual precautions to maintain the airway. General supportive care of the patient is indicated including monitoring of vital signs and observation of the clinical status of the patient. Contact a Certified Poison Control Center for up-to-date information on the management of overdose with pregabalin. Pregabalin can be removed by hemodialysis. Standard hemodialysis procedures result in significant clearance of pregabalin (approximately 50% in 4 hours).
11 DESCRIPTION
Description Section
Pregabalin is described chemically as ( S )-3-(aminomethyl)-5-methylhexanoic acid. The molecular formula is C 8 H 17 NO 2 and the molecular weight is 159.23. The chemical structure of pregabalin is: Pregabalin is a white to off-white, crystalline solid with a pKa 1 of 4.2 and a pKa 2 of 10.6. It is sparingly soluble in water and slightly soluble in methanol. The log of the partition coefficient (n-octanol/0.05M phosphate buffer) at pH 7.4 is – 1.35. Pregabalin capsules are administered orally and are supplied as imprinted hard-shell capsules containing 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg of pregabalin, USP, along with lactose monohydrate and talc as inactive ingredients. The capsule shells contain gelatin, iron oxide black (200 mg and 225 mg), iron oxide red (75 mg, 100 mg, 200 mg, 225 mg and 300 mg) sodium lauryl sulfate and titanium dioxide. The imprinting black ink contains black iron oxide, butyl alcohol, potassium hydroxide, propylene glycol, shellac and strong ammonia solution.
12 CLINICAL PHARMACOLOGY
Clinical Pharmacology Section
13 NONCLINICAL TOXICOLOGY
Nonclinical Toxicology Section
14 CLINICAL STUDIES
Clinical Studies Section
16 HOW SUPPLIED/STORAGE AND HANDLING
How Supplied Section
25 mg capsules: Hard gelatin capsules, size ‘4’ White colored cap and White colored body with “686” and two vertical Bars imprinted in black ink on cap and body, containing white to off white free flowing granules. Bottles of 30 with Child Resistant Cap……………..NDC 47335-686-83 Bottles of 100 with Child Resistant Cap……………NDC 47335-686-88 Bottles of 100………NDC 47335-686-08 Bottles of 1000……..NDC 47335-686-18 50 mg capsules: Hard gelatin capsules, size ‘4’ White colored cap and White colored body with “687” imprinted in black ink on cap and body, containing white to off white free flowing granules. Bottles of 30 with Child Resistant Cap……………..NDC 47335-687-83 Bottles of 100 with Child Resistant Cap……………NDC 47335-687-88 Bottles of 100………NDC 47335-687-08 Bottles of 1000……..NDC 47335-687-18 75 mg capsules: Hard gelatin capsules, size ‘4’ Orange colored cap and White colored body with “688” imprinted in black ink on cap and body, containing white to off white free flowing granules. Bottles of 30 with Child Resistant Cap……………..NDC 47335-688-83 Bottles of 100 with Child Resistant Cap……………NDC 47335-688-88 Bottles of 100 ………NDC 47335-688-08 Bottles of 1000 ……..NDC 47335-688-18 100 mg capsules: Hard gelatin capsules, size ‘3’ Orange colored cap and Orange colored body with “689” imprinted in black ink on cap and body, containing white to off white free flowing granules. Bottles of 30 with Child Resistant Cap……………..NDC 47335-689-83 Bottles of 100 with Child Resistant Cap……………NDC 47335-689-88 Bottles of 100 ………NDC 47335-689-08 Bottles of 1000 ……..NDC 47335-689-18 150 mg capsules: Hard gelatin capsules, size ‘1’ White colored cap and White colored body with “690” imprinted in black ink on cap and body, containing white to off white free flowing granules. Bottles of 30 with Child Resistant Cap……………..NDC 47335-690-83 Bottles of 100 with Child Resistant Cap……………NDC 47335-690-88 Bottles of 100 ………NDC 47335-690-08 Bottles of 1000 ……..NDC 47335-690-18 200 mg capsules: Hard gelatin capsules, size ‘0’ Light Orange colored cap and Light Orange colored body with “691” imprinted in black ink on cap and body, containing white to off white free flowing granules. Bottles of 30 with Child Resistant Cap……………..NDC 47335-691-83 Bottles of 100 with Child Resistant Cap……………NDC 47335-691-88 Bottles of 100 ………NDC 47335-691-08 Bottles of 1000 ……..NDC 47335-691-18 225 mg capsules: Hard gelatin capsules, size ‘0’ Light Orange colored cap and White colored body with “692” imprinted in black ink on cap and body, containing white to off white free flowing granules. Bottles of 30 with Child Resistant Cap……………..NDC 47335-692-83 Bottles of 100 with Child Resistant Cap……………NDC 47335-692-88 Bottles of 100 ………NDC 47335-692-08 Bottles of 1000……..NDC 47335-692-18 300 mg capsules: Hard gelatin capsules, size ‘00’ Orange colored cap and White colored body with “693” imprinted in black ink on cap and body, containing white to off white free flowing granules. Bottles of 30 with Child Resistant Cap……………..NDC 47335-693-83 Bottles of 100 with Child Resistant Cap……………NDC 47335-693-88 Bottles of 100………NDC 47335-693-08 Bottles of 1000 ……..NDC 47335-693-18 Storage and Handling Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Dispense in tight containers (USP).
17 PATIENT COUNSELING INFORMATION
Information For Patients Section
Advise the patient to read the FDA-approved patient labeling (Medication Guide). Angioedema Advise patients that pregabalin capsules may cause angioedema, with swelling of the face, mouth (lip, gum, tongue) and neck (larynx and pharynx) that can lead to life-threatening respiratory compromise. Instruct patients to discontinue pregabalin capsules and immediately seek medical care if they experience these symptoms [ see Warnings and Precautions ( 5.1 ) ]. Hypersensitivity Advise patients that pregabalin capsules have been associated with hypersensitivity reactions such as wheezing, dyspnea, rash, hives, and blisters. Instruct patients to discontinue pregabalin capsules and immediately seek medical care if they experience these symptoms [see Warnings and Precautions ( 5.2 ) ]. Suicidal Thinking and Behavior Patients, their caregivers, and families should be counseled that AEDs, including pregabalin capsules, may increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Report behaviors of concern immediately to healthcare providers [see Warnings and Precautions (5.3)]. Respiratory Depression Inform patients about the risk of respiratory depression. Include information that the risk is greatest for those using concomitant central nervous system (CNS) depressants (such as opioid analgesics) or in those with underlying respiratory impairment. Teach patients how to recognize respiratory depression and advise them to seek medical attention immediately if it occurs [see Warnings and Precautions (5.4)]. Dizziness and Somnolence Counsel patients that pregabalin capsules may cause dizziness, somnolence, blurred vision and other CNS signs and symptoms. Accordingly, advise patients not to drive, operate complex machinery, or engage in other hazardous activities until they have gained sufficient experience on pregabalin capsules to gauge whether or not it affects their mental, visual, and/or motor performance adversely [see Warnings and Precautions (5.5)]. CNS Depressants Inform patients who require concomitant treatment with central nervous system depressants such as opiates or benzodiazepines that they may experience additive CNS side effects, such as respiratory depression, somnolence and dizziness [see Warnings and Precautions (5.4, 5.5) and Drug Interactions (7)]. Advise patients to avoid consuming alcohol while taking pregabalin capsules, as pregabalin capsules may potentiate the impairment of motor skills and sedating effects of alcohol. Adverse Reactions with Abrupt or Rapid Discontinuation Advise patients to take pregabalin as prescribed. Abrupt or rapid discontinuation may result in increased seizure frequency in patients with seizure disorders, and insomnia, nausea, headache, anxiety, hyperhidrosis, or diarrhea [see Warnings and Precautions (5.6)]. Missed Dose Counsel patients if they miss a dose, they should take it as soon as they remember. If it is almost time for the next dose, they should skip the missed dose and take the next dose at their regularly scheduled time. Instruct patients not to take two doses at the same time. Weight Gain and Edema Counsel patients that pregabalin capsules may cause edema and weight gain. Advise patients that concomitant treatment with pregabalin capsules and a thiazolidinedione antidiabetic agent may lead to an additive effect on edema and weight gain. For patients with preexisting cardiac conditions, this may increase the risk of heart failure [see Warnings and Precautions (5.7, 5.8)]. Ophthalmological Effects Counsel patients that pregabalin capsules may cause visual disturbances. Inform patients that if changes in vision occur, they should notify their physician [see Warnings and Precautions (5.10)] . Creatine Kinase Elevations Instruct patients to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever [see Warnings and Precautions (5.11)] . Pregnancy There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to pregabalin capsules during pregnancy [see Use in Specific Populations (8.1)] . Lactation Advise nursing mothers that breastfeeding is not recommended during treatment with pregabalin capsules [see Use in Specific Populations (8.2)] . Male Fertility Inform men being treated with pregabalin capsules who plan to father a child of the potential risk of male-mediated teratogenicity. In preclinical studies in rats, pregabalin was associated with an increased risk of male-mediated teratogenicity. The clinical significance of this finding is uncertain [see Nonclinical Toxicology (13.1) and Use in Specific populations (8.3)]. Dermatopathy Instruct diabetic patients to pay particular attention to skin integrity while being treated with pregabalin capsules and to inform their healthcare provider about any sores or skin problems. Some animals treated with pregabalin developed skin ulcerations, although no increased incidence of skin lesions associated with pregabalin capsules was observed in clinical trials [see Nonclinical Toxicology (13.2)] . Dispense with Medication Guide available at: https://www.sunpharma.com/usa/products
MEDICATION GUIDE
SPL MEDGUIDE SECTION
Pregabalin (pre GAB a lin) Capsules CV Read this Medication Guide before you start taking pregabalin capsules and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. If you have any questions about pregabalin capsules, ask your healthcare provider or pharmacist. What is the most important information I should know about pregabalin capsule? Pregabalin capsule may cause serious side effects including: serious, even life-threatening, allergic reactions suicidal thoughts or actions serious breathing problems swelling of your hands, legs and feet dizziness and sleepiness These serious side effects are described below: Serious, even life-threatening, allergic reactions. Stop taking pregabalin capsules and call your healthcare provider right away if you have any of these signs of a serious allergic reaction: swelling of your face, mouth, lips, gums, tongue, throat or neck trouble breathing rash, hives (raised bumps) or blisters Like other antiepileptic drugs, pregabalin capsules may cause suicidal thoughts or actions in a very small number of people, about 1 in 500. Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying attempts to commit suicide new or worse depression new or worse anxiety feeling agitated or restless panic attacks trouble sleeping (insomnia) new or worse irritability acting aggressive, being angry, or violent acting on dangerous impulses an extreme increase in activity and talking (mania) other unusual changes in behavior or mood If you have suicidal thoughts or actions, do not stop pregabalin capsules without first talking to a healthcare provider. Stopping pregabalin capsules suddenly can cause serious problems. Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes. How can I watch for early symptoms of suicidal thoughts and actions? Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you are worried about symptoms. Serious breathing problems can occur when pregabalin capsules are taken with other medicines that can cause severe sleepiness or decreased awareness, or when it is taken by someone who already has breathing problems. Watch for increased sleepiness or decreased breathing when starting pregabalin capsules or when the dose is increased. Get help right away if breathing problems occur. Swelling of your hands, legs and feet. This swelling can be a serious problem for people with heart problems. Dizziness and sleepiness. Do not drive a car, work with machines, or do other dangerous activities until you know how pregabalin capsules affect you. Ask your healthcare provider about when it will be okay to do these activities. What are pregabalin capsules? Pregabalin capsules are a prescription medicine used in adults, 18 years of age and older to treat: pain from damaged nerves (neuropathic pain) that happens with diabetes pain from damaged nerves (neuropathic pain) that follows healing of shingles fibromyalgia (pain all over your body) pain from damaged nerves (neuropathic pain) that follows spinal cord injury It is not known if pregabalin capsule is safe and effective in people under 18 years of age for the treatment of fibromyalgia and neuropathic pain with diabetes, shingles, or spinal cord injury. Pregabalin capsules are a prescription medicine used in people 1 month of age and older to treat: partial-onset seizures when taken together with other seizure medicines. For the treatment of partial-onset seizures when taken together with other seizure medicines, it is not known if pregabalin capsules are safe and effective in children under 1 month of age. Who should not take pregabalin capsules? Do not take pregabalin capsules if you are allergic to pregabalin or any of the ingredients in pregabalin capsules. See “What is the most important information I should know about pregabalin capsules?” for the signs of an allergic reaction. See the end of this Medication Guide for a complete list of ingredients in pregabalin capsules. What should I tell my healthcare provider before taking pregabalin capsules? Before taking pregabalin capsules, tell your healthcare provider about all your medical conditions, including if you: have or have had depression, mood problems or suicidal thoughts or behavior. have breathing problems. have kidney problems or get kidney dialysis. have heart problems including heart failure. have a bleeding problem or a low blood platelet count. have abused prescription medicines, street drugs, or alcohol in the past. have ever had swelling of your face, mouth, tongue, lips, gums, neck, or throat (angioedema). plan to father a child. Animal studies have shown that pregabalin, the active ingredient in pregabalin capsules, made male animals less fertile and caused sperm to change. Also, in animal studies, birth defects were seen in the offspring (babies) of male animals treated with pregabalin. It is not known if these problems can happen in people who take pregabalin capsules. are pregnant or plan to become pregnant. Pregabalin capsules may harm your unborn baby. You and your healthcare provider will decide if you should take pregabalin capsules while you are pregnant. If you become pregnant while taking pregabalin capsules, talk to your healthcare provider about registering with the North American Antiepileptic Drug Pregnancy Registry. You can enroll in this registry by calling 1-888-233-2334. The purpose of this registry is to collect information about the safety of antiepileptic drugs during pregnancy. Information about the registry can also be found at the website, http://www.aedpregnancyregistry.org/. are breastfeeding or plan to breastfeed. Pregabalin passes into your breast milk. It is not known if pregabalin capsules can harm your baby. Talk to your healthcare provider about the best way to feed your baby if you take pregabalin capsules. Breastfeeding is not recommended while taking pregabalin capsules . Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins or herbal supplements. Pregabalin capsules and other medicines may affect each other causing side effects. Especially tell your healthcare provider if you take: angiotensin converting enzyme (ACE) inhibitors, which are used to treat many conditions, including high blood pressure. You may have a higher chance for swelling and hives if these medicines are taken with pregabalin capsules. Avandia* (rosiglitazone) or Actos* (pioglitazone) for diabetes. You may have a higher chance of weight gain or swelling of your hands or feet if these medicines are taken with pregabalin capsules. any opioid pain medicine (such as oxycodone), or medicines for anxiety (such as lorazepam) or insomnia (such as zolpidem). You may have a higher chance for dizziness, sleepiness or serious breathing problems if these medicines are taken with pregabalin capsules. any medicines that make you sleepy. Know the medicines you take. Keep a list of them with you to show your healthcare provider and pharmacist each time you get a new medicine. Do not start a new medicine without talking with your healthcare provider. How should I take pregabalin capsules? Take pregabalin capsules exactly as prescribed. Your healthcare provider will tell you how many pregabalin capsules to take and when to take them. Pregabalin capsules may be taken with or without food. Your healthcare provider may change your dose. Do not change your dose without talking to your healthcare provider. Do not stop taking pregabalin c...
PRINCIPAL DISPLAY PANEL - 25 mg
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
NDC 47335-686-88 Pregabaling Capsules CV 25 mg PHARMACIST: Dispense with Medication Guide to each patient. Rx only 100 Capsules SUN PHARMA
PRINCIPAL DISPLAY PANEL - 50 mg
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
NDC 47335-687-88 Pregabaling Capsules CV 50 mg PHARMACIST: Dispense with Medication Guide to each patient. Rx only 100 Capsules SUN PHARMA
PRINCIPAL DISPLAY PANEL - 75 mg
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
NDC 47335-688-88 Pregabaling Capsules CV 75 mg PHARMACIST: Dispense with Medication Guide to each patient. Rx only 100 Capsules SUN PHARMA
PRINCIPAL DISPLAY PANEL - 100 mg
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
NDC 47335-689-88 Pregabaling Capsules CV 100 mg PHARMACIST: Dispense with Medication Guide to each patient. Rx only 100 Capsules SUN PHARMA
PRINCIPAL DISPLAY PANEL - 150 mg
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
NDC 47335-690-88 Pregabaling Capsules CV 150 mg PHARMACIST: Dispense with Medication Guide to each patient. Rx only 100 Capsules SUN PHARMA
PRINCIPAL DISPLAY PANEL - 200 mg
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
NDC 47335-691-88 Pregabaling Capsules CV 200 mg PHARMACIST: Dispense with Medication Guide to each patient. Rx only 100 Capsules SUN PHARMA
PRINCIPAL DISPLAY PANEL - 225 mg
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
NDC 47335-692-88 Pregabaling Capsules CV 225 mg PHARMACIST: Dispense with Medication Guide to each patient. Rx only 100 Capsules SUN PHARMA
PRINCIPAL DISPLAY PANEL - 300 mg
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
NDC 47335-693-88 Pregabaling Capsules CV 300 mg PHARMACIST: Dispense with Medication Guide to each patient. Rx only 100 Capsules SUN PHARMA